Table 3

Productivity costs over 2 years of follow-up.

Tapering csDMARDs first (n=94)Tapering TNF-inhibitor first (n=95)
 Became unemployed, n (%)2 (4)6 (11)
Sick leave (during 2-year follow-up)
 Occurrence, n (%)20 (21)26 (27)
 Long-term sickness, n (%)2 (2)1 (1)
 Days absent, mean (SD)*9.0 (23)12.3 (22)
Contract hours†
 Working hours per week after 2 years, mean (SD)32 (8.9)33 (12)
 Reduction of working hours per week, n (%)8 (8)11 (11)
 Amount of reduction, hours, mean (SD)‡15 (11)19 (17)
Number of patients, n (%)34 (36)41 (43)
 Number of days per month, mean (SD)§5.3 (0.9)6.1 (1.1)
 Average productivity loss, proportion (SD)¶27.9% (13%)26.4% (15%)
  • *Only indicated when patients reported sick leave.

  • †Only indicated when patients had paid work.

  • ‡Only indicated for those with a reduction in working hours.

  • §Average productivity score was only obtained for patients indicating that they had loss of productivity.

  • ¶Productivity loss was indicated only for the days with productivity loss for those who reported to suffer from loss of productivity.

  • csDMARDs, conventional synthetic disease modifying antirheumatic drugs; TNF, tumour necrosis factor.